Table 3.
Proportions of patients who did not receive secondary prevention drugs*
| Aspirin (n=55 994)
|
β blocker (n=55 488)
|
Statin (n=55 791)
|
ACE inhibitor (n=55 277)
|
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| % (C) | % (NC) | C/NC† | % (C) | % (NC) | C/NC† | % (C) | % (NC) | C/NC† | % (C) | % (NC) | C/NC† | |
| Age (years): | ||||||||||||
| <55 | 2.8 | 2.9 | 0.99 | 12.1 | 12.3 | 0.99 | 3.6 | 3.8 | 0.95 | 12.7 | 14.4 | 0.88 |
| 55-64 | 3.6 | 4.0 | 0.91 | 16.0 | 18.6 | 0.86 | 3.6 | 4.0 | 0.89 | 13.1 | 14.6 | 0.90 |
| 65-74 | 5.8 | 7.3 | 0.79 | 22.8 | 27.4 | 0.83 | 4.4 | 6.1 | 0.72 | 16.3 | 17.4 | 0.94 |
| 75-84 | 8.0 | 10.1 | 0.79 | 28.7 | 34.8 | 0.83 | 8.3 | 11.7 | 0.70 | 20.3 | 24.4 | 0.83 |
| ≥85 | 9.8 | 10.1 | 0.96 | 34.5 | 44.6 | 0.77 | 17.8 | 28.8 | 0.62 | 30.2 | 35.0 | 0.86 |
| Age missing | 6.6 | 13.0 | 0.51 | 21.4 | 27.3 | 0.78 | 4.0 | 11.3 | 0.36 | 11.3 | 17.3 | 0.66 |
| Total | 5.5 (1156/20 848) | 7.6 (2663/35 146) | 0.73 | 21.4 (4423/20 685) | 28.6 (9962/34 803) | 0.75 | 5.9 (1220/20 796) | 10.4 (3644/34 995) | 0.56 | 16.7 (3452/20 630) | 21.1 (7318/34 647) | 0.79 |
| Inter-hospital: median (IQR) | 3 (0-7) | 6 (3-10) | 20 (12-29) | 27 (20-35) | 4 (0-8) | 8 (4-13) | 14 (7-21) | 19 (12-25) | ||||
ACE=angiotensin converting enzyme; IQR=interquartile range.
*
Patients for whom treatment was considered to be contraindicated or not indicated or was not given are grouped together. Patients who died in hospital, who were transferred to another hospital, or whose discharge destination was unknown are excluded.
†
Risk ratio for secondary prevention treatment not being used for patients admitted under a cardiologist (C) relative to patients admitted under a non-cardiologist (NC).